Morbidity from CMV Infection in Transplant Patients

Morbidity from CMV Infection in Transplant Patients

Harry Erba, MD, PhD; Mark Levis, MD, PhD; and Roy Chemaly, MD, MPH, describe the morbidity and mortality associated with CMV infection in patients undergoing transplant.

Morbidity from CMV Infection in Transplant Patients
Morbidity from CMV Infection in Transplant Patients
CMV infection after transplant
Infection Prevention: Cytomegalovirus in Post-Transplant Patients
Cytomegalovirus in solid organ transplant recipients
Treating CMV Infection in People Receiving Solid Organ or Hematopoietic Stem Cell Transplantations
Burden of CMV Infection in HSCT Patients
2023 Updates on CMV Management after Kidney Transplant
Letermovir prevents cytomegalovirus (CMV) in transplant patients
CMV infection monitoring after alloHSCT
Burden of CMV Infection in HSCT Patients
Letermovir for CMV Prophylaxis in Transplant Patients
CMV Infections in Kidney Transplant Recipients - Dr. Hannah Kaminski (Bordeaux, France)
Safety and efficacy of letermovir against cytomegalovirus in allogeneic stem cell transplant
Takeda: Define the Transplant Recipient at High-Risk of CMV Infection & Discussion on Unmet Needs
In Which Patients is Cytomegalovirus Most Harmful?
Letermovir for CMV Prophylaxis in Transplant Patients
The importance of educating stem cell transplant recipients on tuberculosis and cytomegalovirus
Letermovir CMV prophylaxis offers survival benefit in hematopoietic cell transplant patients
New Paradigm for Cytomegalovirus Disease Prevention in Transplantation